Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Trimethoprim-Sulfamethoxazole–Induced Hyperkalemia in Patients Receiving Inhibitors of the Renin-Angiotensin System

Trimethoprim-Sulfamethoxazole–Induced Hyperkalemia in Patients Receiving Inhibitors of the... ORIGINAL INVESTIGATION Trimethoprim-Sulfamethoxazole–Induced Hyperkalemia in Patients Receiving Inhibitors of the Renin-Angiotensin System A Population-Based Study Tony Antoniou, BScPharm, PharmD; Tara Gomes, MHSc; David N. Juurlink, MD, PhD; Mona R. Loutfy, MD, MPH; Richard H. Glazier, MD, MPH; Muhammad M. Mamdani, PharmD, MPH Background: Trimethoprim therapy can cause hyper- termined for the association between hyperkalemia- kalemia and is often coprescribed with angiotensin- associated hospitalization and previous antibiotic use. converting enzyme inhibitors (ACEIs) or angiotensin re- ceptor blockers (ARBs). The objective of this study was Results: During the 14-year study period, we identified to characterize the risk of hyperkalemia-associated hos- 4148 admissions involving hyperkalemia, 371 of which oc- pitalization in elderly patients who were being treated curred within 14 days of antibiotic exposure. Compared with trimethoprim-sulfamethoxazole along with either with amoxicillin, the use of trimethoprim-sulfamethoxa- an ACEI or an ARB. zole was associated with a nearly 7-fold increased risk of hyperkalemia-associated hospitalization (adjusted odds ra- Methods: We conducted a population-based, nested case- tio, 6.7; 95% confidence interval, 4.5-10.0). No such risk control study of a cohort of elderly patients 66 years or was found with the use of comparator antibiotics. older who were residents of Ontario, Canada, and who were receiving http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Trimethoprim-Sulfamethoxazole–Induced Hyperkalemia in Patients Receiving Inhibitors of the Renin-Angiotensin System

Loading next page...
 
/lp/american-medical-association/trimethoprim-sulfamethoxazole-induced-hyperkalemia-in-patients-ltjtIzyTkI
Publisher
American Medical Association
Copyright
Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/archinternmed.2010.142
pmid
20585070
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL INVESTIGATION Trimethoprim-Sulfamethoxazole–Induced Hyperkalemia in Patients Receiving Inhibitors of the Renin-Angiotensin System A Population-Based Study Tony Antoniou, BScPharm, PharmD; Tara Gomes, MHSc; David N. Juurlink, MD, PhD; Mona R. Loutfy, MD, MPH; Richard H. Glazier, MD, MPH; Muhammad M. Mamdani, PharmD, MPH Background: Trimethoprim therapy can cause hyper- termined for the association between hyperkalemia- kalemia and is often coprescribed with angiotensin- associated hospitalization and previous antibiotic use. converting enzyme inhibitors (ACEIs) or angiotensin re- ceptor blockers (ARBs). The objective of this study was Results: During the 14-year study period, we identified to characterize the risk of hyperkalemia-associated hos- 4148 admissions involving hyperkalemia, 371 of which oc- pitalization in elderly patients who were being treated curred within 14 days of antibiotic exposure. Compared with trimethoprim-sulfamethoxazole along with either with amoxicillin, the use of trimethoprim-sulfamethoxa- an ACEI or an ARB. zole was associated with a nearly 7-fold increased risk of hyperkalemia-associated hospitalization (adjusted odds ra- Methods: We conducted a population-based, nested case- tio, 6.7; 95% confidence interval, 4.5-10.0). No such risk control study of a cohort of elderly patients 66 years or was found with the use of comparator antibiotics. older who were residents of Ontario, Canada, and who were receiving

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Jun 28, 2010

References